Skip to content

A Randomized Controlled Multi-center Clinical Trial of Acupuncture Combined with Tongqiao Huoxue Mingmu Therapy in the Treatment of Central Retinal Artery Occlusion

A Randomized Controlled Multi-center Clinical Trial of Acupuncture Combined with Tongqiao Huoxue Mingmu Therapy in the Treatment of Central Retinal Artery Occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000033
Enrollment
Unknown
Registered
2025-01-07
Start date
2025-01-10
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Occlusion of the central retinal artery

Interventions

Treatment group: Paracentesis of anterior chamber + Tongqihuoxuemingmu prescription + acupuncture + pentoxifylline for injection + inosine injection + oxygen inhalation
Control group:Paracentesis of anterior chamber + isosorbide nitrate + bulbar injection 654-2+ inosine injection + oxygen inhalation

Sponsors

Eye Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: (1) In line with Western medicine "central retinal artery obstruction" (including complete and incomplete obstruction) traditional Chinese medicine "storm blindness" diagnosis syndrome differentiation as qi stagnation and blood stasis; (2) Patients with disease course within 6h-21 days; (3) Patients who have not received eye treatment; (4) The subjects fully understand the project and voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Unstable vital signs or combined with serious cardiovascular and cerebrovascular diseases or other systemic diseases life-threatening; (2) Patients with optic nerve atrophy; (3) concurrent suffering from other eye diseases (except dry eye senile cataract diabetic retinopathy stage 1-II); (4) Patients who have received eye surgery within six months or general surgery within one year; (5) Received a major external injury to the eye or the whole body one year ago; (6) Pregnant or lactating women; (7) Those who are undergoing other clinical drug trials; (8) Poor compliance do not accept the corresponding treatment; (9) Patients who have undergone thrombolytic therapy.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;

Secondary

MeasureTime frame
Intraocular pressure;Fundus fluorescein angiography;Color Doppler ultrasound of retrobulbar vessels;Visual field;Optical coherence tomography angiography;

Countries

China

Contacts

Public ContactHao Xiaofeng

Eye Hospital China Academy of Chinese Medical Sciences

fmmuhao@163.com13681447077

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026